v3.26.3
Acquisition of Biovire (Tables)
9 Months Ended
Sep. 30, 2026
Business Combination [Abstract]  
Schedule of Purchase Price Allocation
The purchase price allocation is set forth in the table below and represents the Company’s fair value estimates related to the acquisition as of July 20, 2025.
Estimated fair value
Identifiable assets acquired
Cash$4,033 
Current assets2,565 
Operating lease right-of-use assets3,413 
Property and equipment, net16,610 
Intangible assets600 
Total identifiable assets acquired27,221 
Liabilities assumed
Current liabilities2,410 
Operating lease liabilities, non-current portion2,800 
Long-term debt3,000 
Deferred tax liability307 
Other long-term liabilities2,157 
Total liabilities assumed10,674 
Net identifiable assets acquired16,547 
Goodwill10,297 
Total fair value of consideration paid$26,844